EMERYVILLE, CA, Nutcracker Therapeutics, a biotech company developing RNA therapeutics, announced it has raised $167M in Series C financing led by ARCH Venture Partners.
Nutcracker Therapeutics, a biotech company developing RNA therapeutics using its proprietary biochip-based manufacturing platform, today announced it has raised $167 million in Series C financing led by ARCH Venture Partners.
The funds will allow the company to expand and advance its pipeline of mRNA medicines for cancer, in addition to further refining its RNA manufacturing platform and the underlying technology.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
